New drug combo aims to shrink Hard-to-Treat lung tumors
NCT ID NCT07393555
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, sacituzumab govitecan and ivonescimab, alone or together, in people with advanced non-small cell lung cancer that has specific gene changes. The goal is to see if the combination works better than either drug alone at shrinking tumors and delaying cancer growth. About 117 adults whose cancer has returned or spread will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New drug combo shows promise for tough cancers
- New drug combo aims to reboot immune system against lung cancer